Contact us if you would like more information about IntegraGen and our efforts.
09 July 2020 Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) » 09 July 2020 IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) » 10 June 2020 We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience. MERCURY v3.0 has (…) » 13 April 2020 IntegraGen announces the company’s MERCURY™ cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…) » 03 April 2020 +20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020. 31 March 2020 We have undertaken (…) » 26 March 2020 IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…) » 17 March 2020 Dear IntegraGen partner and customer, We value your well-being and understand that the entire community is impacted by the novel coronavirus (COVID-19) outbreak. This is why we are committed to providing consistent and timely support so your important work is not interrupted. IntegraGen is closely monitoring guidance from health authorities (…) » 11 March 2020 IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur. 10 January 2020 IntegraGen announced today its unaudited business figures for the year 2019.Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN
IntegraGen reports sales of €4.7 million in the first half of 2020, up 13%, and cash position of €5.8 million
What’s new with MERCURY?
Our latest release: MERCURY™ v3.0
IntegraGen Achieves CE Mark for Its MERCURY™ Cloud-based Software Tool Which Supports Molecular Tumor Profiling for Cancer Patients
IntegraGen reports 2019 annual results
IntegraGen Update – Still open to meet your research needs
IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.
IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool for oncology sequencing data interpretation and reporting
COVID-19 update: IntegraGen remains committed to meeting our customers needs
IntegraGen renews its agreement with the Institut Pasteur related to high-throughput sequencing for microbiology
IntegraGen announces 2019 revenue of €8.3 million, up +20%, and cash position of €2.8 million as of December 31
